Novartis AG ADR (NYSE: NVS)’s stock price has decreased by -0.79 compared to its previous closing price of 107.75. However, the company has seen a -2.65% decrease in its stock price over the last five trading sessions. proactiveinvestors.co.uk reported 2025-02-11 that Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion.
Is It Worth Investing in Novartis AG ADR (NYSE: NVS) Right Now?
Novartis AG ADR (NYSE: NVS) has a price-to-earnings ratio that is above its average at 18.20x. The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 10 as “hold,” and 2 as “sell.”
The public float for NVS is 1.97B, and at present, short sellers hold a 0.21% of that float. On February 12, 2025, the average trading volume of NVS was 1.50M shares.
NVS’s Market Performance
The stock of Novartis AG ADR (NVS) has seen a -2.65% decrease in the past week, with a 7.69% rise in the past month, and a 0.42% gain in the past quarter. The volatility ratio for the week is 1.49%, and the volatility levels for the past 30 days are at 1.38% for NVS. The simple moving average for the past 20 days is 3.51% for NVS’s stock, with a -0.36% simple moving average for the past 200 days.
NVS Trading at 5.84% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.59% of loss for the given period.
Volatility was left at 1.38%, however, over the last 30 days, the volatility rate increased by 1.49%, as shares surge +7.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.75% upper at present.
During the last 5 trading sessions, NVS fell by -2.83%, which changed the moving average for the period of 200-days by +7.71% in comparison to the 20-day moving average, which settled at $103.27. In addition, Novartis AG ADR saw 9.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 6,566 shares at the price of $111.72 back on Aug 12 ’24. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $733,572 using the latest closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.75 for the gross margin
The net margin for Novartis AG ADR stands at 0.23. The total capital return value is set at 0.2. Equity return is now at value 26.33, with 11.34 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.56. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 14.46.
Currently, EBITDA for the company is 20.71 billion with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 4.47. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
To sum up, Novartis AG ADR (NVS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
